HN2002000153A - Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester. - Google Patents
Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester.Info
- Publication number
- HN2002000153A HN2002000153A HN2002000153A HN2002000153A HN2002000153A HN 2002000153 A HN2002000153 A HN 2002000153A HN 2002000153 A HN2002000153 A HN 2002000153A HN 2002000153 A HN2002000153 A HN 2002000153A HN 2002000153 A HN2002000153 A HN 2002000153A
- Authority
- HN
- Honduras
- Prior art keywords
- cholesterile
- ester
- inhibitors
- emulsioning
- formulations
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/4418—Non condensed pyridines; Hydrogenated derivatives thereof having a carbocyclic group directly attached to the heterocyclic ring, e.g. cyproheptadine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/21—Esters, e.g. nitroglycerine, selenocyanates
- A61K31/255—Esters, e.g. nitroglycerine, selenocyanates of sulfoxy acids or sulfur analogues thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/4196—1,2,4-Triazoles
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4706—4-Aminoquinolines; 8-Aminoquinolines, e.g. chloroquine, primaquine
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/47—Quinolines; Isoquinolines
- A61K31/4709—Non-condensed quinolines and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/10—Dispersions; Emulsions
- A61K9/107—Emulsions ; Emulsion preconcentrates; Micelles
- A61K9/1075—Microemulsions or submicron emulsions; Preconcentrates or solids thereof; Micelles, e.g. made of phospholipids or block copolymers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/06—Antihyperlipidemics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
- A61K9/4841—Filling excipients; Inactive ingredients
- A61K9/4858—Organic compounds
Abstract
ESTA INVENCION SE REFIERE A FORMULACIONES ENCAPSULADAS DE LA PROTEINA DE TRANSFERENCIA DE COLESTERIL ESTER (CETP) PARA USO EN MAMIFEROS, ESPECIALMENTE EN SERES HUMANOS, QUE PROPORCIONAN MAYORES CONCENTRACIONES DE INHIBIDORES DE CETP PARA LA ABSORCION Y, POR LO MTANTO, UNA MAOR BIODISPONIBILIDAD.
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US30002801P | 2001-06-21 | 2001-06-21 |
Publications (1)
Publication Number | Publication Date |
---|---|
HN2002000153A true HN2002000153A (es) | 2002-11-05 |
Family
ID=23157363
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
HN2002000153A HN2002000153A (es) | 2001-06-21 | 2002-06-20 | Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester. |
Country Status (33)
Country | Link |
---|---|
US (2) | US6962931B2 (es) |
EP (1) | EP1453544A2 (es) |
JP (1) | JP2005500314A (es) |
KR (1) | KR20040015746A (es) |
CN (1) | CN1635911A (es) |
AP (1) | AP2002002559A0 (es) |
AR (1) | AR034599A1 (es) |
BG (1) | BG108486A (es) |
BR (1) | BR0210505A (es) |
CA (1) | CA2455288A1 (es) |
CR (1) | CR7163A (es) |
CZ (1) | CZ20033341A3 (es) |
EA (1) | EA200301139A1 (es) |
EC (1) | ECSP034875A (es) |
EE (1) | EE200400024A (es) |
GT (1) | GT200200124A (es) |
HN (1) | HN2002000153A (es) |
HU (1) | HUP0400263A2 (es) |
IL (1) | IL158765A0 (es) |
IS (1) | IS7014A (es) |
MA (1) | MA27034A1 (es) |
MX (1) | MXPA04000014A (es) |
NO (1) | NO20035632L (es) |
OA (1) | OA12619A (es) |
PA (1) | PA8548601A1 (es) |
PE (1) | PE20030128A1 (es) |
PL (1) | PL368850A1 (es) |
SK (1) | SK15172003A3 (es) |
SV (1) | SV2003001103A (es) |
TN (1) | TNSN03139A1 (es) |
UY (1) | UY27344A1 (es) |
WO (1) | WO2003000295A2 (es) |
ZA (1) | ZA200308561B (es) |
Families Citing this family (73)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
IL143604A0 (en) * | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
US7732404B2 (en) * | 1999-12-30 | 2010-06-08 | Dexcel Ltd | Pro-nanodispersion for the delivery of cyclosporin |
JP4031232B2 (ja) * | 2001-11-09 | 2008-01-09 | カプスゲル・ジャパン株式会社 | 新規カプセル |
ES2305434T3 (es) | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
CA2478433C (en) * | 2002-03-01 | 2009-12-08 | Cesi Chemical, A Flotek Company | Composition and process for well cleaning |
US20040175341A1 (en) * | 2003-03-04 | 2004-09-09 | Manning Monna Marie | Microemulsion for cosmetic or pharmaceutical use containing an active ingredient |
JP2006520810A (ja) * | 2003-03-17 | 2006-09-14 | 日本たばこ産業株式会社 | S−[2−([[1−(2−エチルブチル)シクロヘキシル]カルボニル]アミノ)フェニル]2−メチルプロパンチオエートの経口吸収性を増加させる方法 |
CN101036636A (zh) * | 2003-03-17 | 2007-09-19 | 日本烟草产业株式会社 | 提高s-[2-([[1-(2-乙基丁基)环己基]羰基]氨基)苯基]-2-甲基丙硫代酸酯口服生物利用度的方法 |
ES2377121T3 (es) * | 2003-03-17 | 2012-03-22 | Japan Tobacco Inc. | Composiciones farmacéuticas de inhibidores de CETP |
TWI494102B (zh) * | 2003-05-02 | 2015-08-01 | Japan Tobacco Inc | 包含s-〔2(〔〔1-(2-乙基丁基)環己基〕羰基〕胺基)苯基〕2-甲基丙烷硫酯及hmg輔酶a還原酶抑制劑之組合 |
MXPA06001417A (es) * | 2003-08-04 | 2006-05-15 | Pfizer Prod Inc | Composiciones farmaceuticas de adsorbatos de farmacos amorfos y materiales que forman microfases lipofilas. |
EP1670765A2 (en) * | 2003-09-30 | 2006-06-21 | Pfizer Products Inc. | Cetp inhibitors and metabolites thereof |
DK1670768T3 (da) * | 2003-10-08 | 2009-11-09 | Lilly Co Eli | Forbindelser og fremgangsmåder til at behandle dyslipidæmi |
US20050220866A1 (en) * | 2004-04-02 | 2005-10-06 | Dr. Reddy's Laboratories Limited | Novel capsule formulations of etoposide for oral use |
WO2006069162A1 (en) | 2004-12-20 | 2006-06-29 | Reddy Us Therapeutics, Inc. | Novel heterocyclic compounds and their pharmaceutical compositions |
KR101238525B1 (ko) | 2004-12-31 | 2013-02-28 | 레디 유에스 테라퓨틱스 인코포레이티드 | Cetp 저해제로서의 신규 벤질아민 유도체 |
US8604055B2 (en) | 2004-12-31 | 2013-12-10 | Dr. Reddy's Laboratories Ltd. | Substituted benzylamino quinolines as cholesterol ester-transfer protein inhibitors |
WO2006085217A2 (en) * | 2005-02-08 | 2006-08-17 | Pfizer Products Inc. | Solid adsorbates of hydrophobic drugs |
US7623458B2 (en) * | 2005-09-30 | 2009-11-24 | The Boeing Company | System and method for providing integrated services across cryptographic boundaries in a network |
ATE516016T1 (de) | 2005-12-05 | 2011-07-15 | Merck Sharp & Dohme | Selbstemulgierende formulierungen von cetp- hemmern |
WO2007076699A1 (fr) * | 2005-12-31 | 2007-07-12 | Tianjin Tasly Pharmaceutical Co. Ltd., China | Composition pharmaceutique contenant un extrait de chenopodium ambrosioides et son procédé de préparation et son application |
JP2009542677A (ja) * | 2006-06-30 | 2009-12-03 | シェーリング コーポレイション | トロンビン受容体拮抗薬の固形製剤 |
EP1961412A1 (en) * | 2006-12-27 | 2008-08-27 | LEK Pharmaceuticals D.D. | Self-microemulsifying drug delivery systems |
US9222013B1 (en) | 2008-11-13 | 2015-12-29 | Cesi Chemical, Inc. | Water-in-oil microemulsions for oilfield applications |
WO2010066593A1 (en) * | 2008-12-08 | 2010-06-17 | F. Hoffmann-La Roche Ag | Combined drug administration |
US20100273730A1 (en) * | 2009-04-27 | 2010-10-28 | Innopharmax, Inc. | Self-emulsifying pharmaceutical compositions of hydrophilic drugs and preparation thereof |
RU2012101214A (ru) | 2009-06-16 | 2013-07-27 | Пфайзер Инк. | Лекарственные формы апиксабана |
CA2835912A1 (en) * | 2011-05-20 | 2012-11-29 | Aventis Pharmaceuticals Inc. | Pharmaceutical composition comprising fexofenadine |
US9199967B2 (en) | 2011-08-18 | 2015-12-01 | Dr. Reddy's Laboratories Ltd. | Substituted heterocyclic amine compounds as cholestryl ester-transfer protein (CETP) inhibitors |
CA2850022C (en) | 2011-09-27 | 2018-05-01 | Dr. Reddy's Laboratories, Ltd. | 5 - benzylaminomethyl - 6 - aminopyrazolo [3,4-b] pyridine derivatives as cholesteryl ester-transfer protein (cetp) inhibitors useful for the treatment of atherosclerosis |
EP2768486B1 (en) * | 2011-10-21 | 2018-10-03 | First Tech International Limited | Tocotrienol compositions |
DK2838970T3 (en) | 2012-04-15 | 2017-03-20 | Flotek Chemistry Llc | Density formulations for foam filling |
US9200192B2 (en) | 2012-05-08 | 2015-12-01 | Cesi Chemical, Inc. | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
US11407930B2 (en) | 2012-05-08 | 2022-08-09 | Flotek Chemistry, Llc | Compositions and methods for enhancement of production of liquid and gaseous hydrocarbons |
US20160000799A1 (en) * | 2013-02-21 | 2016-01-07 | Dr. Reddy's Laboratories Ltd. | Pharmaceutical compositions of cetp inhibitors |
US10421707B2 (en) | 2013-03-14 | 2019-09-24 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
US9321955B2 (en) | 2013-06-14 | 2016-04-26 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US11180690B2 (en) | 2013-03-14 | 2021-11-23 | Flotek Chemistry, Llc | Diluted microemulsions with low surface tensions |
US9428683B2 (en) | 2013-03-14 | 2016-08-30 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US10000693B2 (en) | 2013-03-14 | 2018-06-19 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10053619B2 (en) | 2013-03-14 | 2018-08-21 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
US10577531B2 (en) | 2013-03-14 | 2020-03-03 | Flotek Chemistry, Llc | Polymers and emulsions for use in oil and/or gas wells |
US10590332B2 (en) | 2013-03-14 | 2020-03-17 | Flotek Chemistry, Llc | Siloxane surfactant additives for oil and gas applications |
US9868893B2 (en) | 2013-03-14 | 2018-01-16 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US9884988B2 (en) | 2013-03-14 | 2018-02-06 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10941106B2 (en) | 2013-03-14 | 2021-03-09 | Flotek Chemistry, Llc | Methods and compositions incorporating alkyl polyglycoside surfactant for use in oil and/or gas wells |
US10287483B2 (en) | 2013-03-14 | 2019-05-14 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells comprising a terpene alcohol |
US10717919B2 (en) | 2013-03-14 | 2020-07-21 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US9068108B2 (en) | 2013-03-14 | 2015-06-30 | Cesi Chemical, Inc. | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
US11254856B2 (en) | 2013-03-14 | 2022-02-22 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US9464223B2 (en) | 2013-03-14 | 2016-10-11 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
CN104706586A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种丁酸氯维地平脂肪乳浓缩液、其制备方法及用途 |
CN104706587A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种依托咪酯脂肪乳浓缩液、其制备方法及用途 |
CN104706689A (zh) * | 2013-12-16 | 2015-06-17 | 天津迈迪瑞康生物医药科技有限公司 | 一种鸦胆子油脂肪乳浓缩液、其制备方法及用途 |
US9890625B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with an obstruction material |
US9890624B2 (en) | 2014-02-28 | 2018-02-13 | Eclipse Ior Services, Llc | Systems and methods for the treatment of oil and/or gas wells with a polymeric material |
US9505970B2 (en) | 2014-05-14 | 2016-11-29 | Flotek Chemistry, Llc | Methods and compositions for use in oil and/or gas wells |
US10294757B2 (en) | 2014-07-28 | 2019-05-21 | Flotek Chemistry, Llc | Methods and compositions related to gelled layers in oil and/or gas wells |
TWI728959B (zh) | 2014-11-04 | 2021-06-01 | 因華生技製藥股份有限公司 | 不穩定或難溶藥物的口服投予 |
CN104546710A (zh) * | 2014-12-20 | 2015-04-29 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹纳米乳及其制备方法 |
CN104490775A (zh) * | 2014-12-20 | 2015-04-08 | 长沙佰顺生物科技有限公司 | 一种安塞曲匹脂肪乳及其制备方法 |
KR101590072B1 (ko) * | 2014-12-23 | 2016-01-29 | 한미약품 주식회사 | 두타스테라이드를 포함하는 자가유화 약물전달 시스템용 조성물 |
EA038013B1 (ru) | 2015-05-28 | 2021-06-23 | Др. Редди'С Лабораториз Лтд. | Пероральная композиция целекоксиба для лечения боли |
SG11201808949SA (en) | 2016-04-15 | 2018-11-29 | Novira Therapeutics Inc | Combinations and methods comprising a capsid assembly inhibitor |
US10934472B2 (en) | 2017-08-18 | 2021-03-02 | Flotek Chemistry, Llc | Compositions comprising non-halogenated solvents for use in oil and/or gas wells and related methods |
US11053433B2 (en) | 2017-12-01 | 2021-07-06 | Flotek Chemistry, Llc | Methods and compositions for stimulating the production of hydrocarbons from subterranean formations |
AU2019235522A1 (en) | 2018-03-14 | 2020-09-03 | Janssen Sciences Ireland Unlimited Company | Capsid assembly modulator dosing regimen |
BR112021009967A2 (pt) * | 2018-11-26 | 2021-08-17 | Hepion Pharmaceuticals, Inc. | formulações farmacêuticas de análogos de ciclosporina |
EA202192793A1 (ru) * | 2019-04-11 | 2022-01-12 | Ар.Пи. ШЕРЕР ТЕКНОЛОДЖИЗ, ЭлЭлСи | Композиция для пероральной доставки белков, пептидов и малых молекул со слабой проницаемостью |
CN110252395B (zh) * | 2019-07-01 | 2020-10-16 | 湖北远大生命科学与技术有限责任公司 | 一种用于制备高纯度牛磺酸的催化剂及其应用 |
US11104843B2 (en) | 2019-10-10 | 2021-08-31 | Flotek Chemistry, Llc | Well treatment compositions and methods comprising certain microemulsions and certain clay control additives exhibiting synergistic effect of enhancing clay swelling protection and persistency |
FR3110852B1 (fr) | 2020-05-27 | 2024-03-15 | Centre Nat Rech Scient | Emulsions pour liberation controlee de medicaments |
US11512243B2 (en) | 2020-10-23 | 2022-11-29 | Flotek Chemistry, Llc | Microemulsions comprising an alkyl propoxylated sulfate surfactant, and related methods |
Family Cites Families (31)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FI65914C (fi) * | 1978-03-07 | 1984-08-10 | Sandoz Ag | Foerfarande foer framstaellning av farmaceutiska kompositionerinnehaollande cyklosporin a |
GB9208712D0 (en) | 1992-04-22 | 1992-06-10 | Sandoz Ltd | Pharmaceutical compositions containing cyclosporin derivates |
AU2517095A (en) | 1994-05-19 | 1995-12-18 | R.P. Scherer International Corporation | Solutions of aryl or heteroaryl substituted alkanoic acids in lipophilic solvents and soft gelatin capsules containing such solutions |
US5965160A (en) * | 1995-04-24 | 1999-10-12 | Yissum Research Development Company Of The Hebrew University Of Jerusalem | Self-emulsifiable formulation producing an oil-in-water emulsion |
GB9608719D0 (en) | 1996-04-26 | 1996-07-03 | Scherer Ltd R P | Pharmaceutical compositions |
US5993858A (en) * | 1996-06-14 | 1999-11-30 | Port Systems L.L.C. | Method and formulation for increasing the bioavailability of poorly water-soluble drugs |
US5958876A (en) * | 1996-06-19 | 1999-09-28 | Novartis Ag | Cyclosporin-containing pharmaceutical compositions |
PT1413297E (pt) | 1996-06-19 | 2008-07-28 | Novartis Ag | Preparações contendo ciclosporina |
JP2894445B2 (ja) * | 1997-02-12 | 1999-05-24 | 日本たばこ産業株式会社 | Cetp活性阻害剤として有効な化合物 |
AU9297798A (en) * | 1997-09-16 | 1999-04-05 | G.D. Searle & Co. | Substituted 1,2,4-triazoles useful for inhibiting cholesteryl ester transfer protein activity |
DE19741399A1 (de) * | 1997-09-19 | 1999-03-25 | Bayer Ag | Tetrahydrochinoline |
US6063762A (en) | 1997-12-05 | 2000-05-16 | Chong Kun Dang Corp. | Cyclosporin-containing microemulsion preconcentrate composition |
AU3285499A (en) * | 1998-02-13 | 1999-08-30 | G.D. Searle & Co. | Substituted pyridines useful for inhibiting cholesteryl ester transfer protein activity |
US6147090A (en) | 1998-09-17 | 2000-11-14 | Pfizer Inc. | 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6197786B1 (en) * | 1998-09-17 | 2001-03-06 | Pfizer Inc | 4-Carboxyamino-2-substituted-1,2,3,4-tetrahydroquinolines |
GT199900147A (es) * | 1998-09-17 | 1999-09-06 | 1, 2, 3, 4- tetrahidroquinolinas 2-sustituidas 4-amino sustituidas. | |
US6147089A (en) * | 1998-09-17 | 2000-11-14 | Pfizer Inc. | Annulated 4-carboxyamino-2-methyl-1,2,3,4,-tetrahydroquinolines |
US6140342A (en) * | 1998-09-17 | 2000-10-31 | Pfizer Inc. | Oxy substituted 4-carboxyamino-2-methyl-1,2,3,4-tetrahydroquinolines |
CA2345108A1 (en) * | 1998-09-25 | 2000-04-06 | Monsanto Company | Substituted n-aliphatic-n-aromatic tertiary-heteroalkylamines useful for inhibiting cholesteryl ester transfer protein activity |
IL143604A0 (en) | 1998-12-30 | 2002-04-21 | Dexcel Ltd | Dispersable concentrate for the delivery of cyclosporin |
CO5271716A1 (es) * | 1999-11-30 | 2003-04-30 | Pfizer Prod Inc | Cristales de 4- carboxamino 1,2,3,4-tetrahidroquinolina 2- sustituida |
US6482862B1 (en) * | 1999-12-20 | 2002-11-19 | G.D. Searle & Co. | Method of using substituted N-benzyl-N-phenyl aminoalcohols for inhibiting cholesteryl ester transfer protein activity |
US7115279B2 (en) * | 2000-08-03 | 2006-10-03 | Curatolo William J | Pharmaceutical compositions of cholesteryl ester transfer protein inhibitors |
CA2448864C (en) * | 2001-06-22 | 2008-04-22 | Pfizer Products Inc. | Pharmaceutical compositions containing a solid dispersion of a poorly-soluble drug in a matrix and a solubility-enhancing polymer |
MXPA03011935A (es) * | 2001-06-22 | 2004-03-26 | Pfizer Prod Inc | Composiciones farmaceuticas que contienen conjuntos de polimero y farmaco. |
ATE444060T1 (de) * | 2001-06-22 | 2009-10-15 | Pfizer Prod Inc | Pharmazeutische zusammensetzungen enthaltend dispersionen aus arzneistoffen und neutralen polymeren |
EP1269994A3 (en) * | 2001-06-22 | 2003-02-12 | Pfizer Products Inc. | Pharmaceutical compositions comprising drug and concentration-enhancing polymers |
ES2305434T3 (es) * | 2002-02-01 | 2008-11-01 | Pfizer Products Inc. | Composiciones framaceuticas de dispersiones amorfas de farmacos y materiales que forman microfases lipofilas. |
CA2474835A1 (en) * | 2002-02-01 | 2003-08-07 | Pfizer Products Inc. | Immediate release dosage forms containing solid drug dispersions |
US20040132771A1 (en) * | 2002-12-20 | 2004-07-08 | Pfizer Inc | Compositions of choleseteryl ester transfer protein inhibitors and HMG-CoA reductase inhibitors |
ES2300628T3 (es) * | 2002-12-20 | 2008-06-16 | Pfizer Products Inc. | Formas de dosificacion que comprenden un inhibidor de cetp y un inhibidor de la hmg-coa reductasa. |
-
2002
- 2002-05-03 IL IL15876502A patent/IL158765A0/xx unknown
- 2002-05-03 MX MXPA04000014A patent/MXPA04000014A/es active IP Right Grant
- 2002-05-03 TN TNPCT/IB2002/001571A patent/TNSN03139A1/fr unknown
- 2002-05-03 HU HU0400263A patent/HUP0400263A2/hu unknown
- 2002-05-03 SK SK1517-2003A patent/SK15172003A3/sk not_active Application Discontinuation
- 2002-05-03 KR KR10-2003-7016651A patent/KR20040015746A/ko not_active Application Discontinuation
- 2002-05-03 CN CNA028124820A patent/CN1635911A/zh active Pending
- 2002-05-03 CA CA002455288A patent/CA2455288A1/en not_active Abandoned
- 2002-05-03 EE EEP200400024A patent/EE200400024A/xx unknown
- 2002-05-03 CZ CZ20033341A patent/CZ20033341A3/cs unknown
- 2002-05-03 WO PCT/IB2002/001571 patent/WO2003000295A2/en active Application Filing
- 2002-05-03 JP JP2003506937A patent/JP2005500314A/ja active Pending
- 2002-05-03 EP EP02732994A patent/EP1453544A2/en not_active Withdrawn
- 2002-05-03 PL PL02368850A patent/PL368850A1/xx not_active Application Discontinuation
- 2002-05-03 OA OA1200300317A patent/OA12619A/en unknown
- 2002-05-03 EA EA200301139A patent/EA200301139A1/ru unknown
- 2002-05-03 BR BR0210505-5A patent/BR0210505A/pt not_active IP Right Cessation
- 2002-06-19 PE PE2002000528A patent/PE20030128A1/es not_active Application Discontinuation
- 2002-06-19 AR ARP020102297A patent/AR034599A1/es unknown
- 2002-06-19 US US10/175,643 patent/US6962931B2/en not_active Expired - Fee Related
- 2002-06-19 GT GT200200124A patent/GT200200124A/es unknown
- 2002-06-20 HN HN2002000153A patent/HN2002000153A/es unknown
- 2002-06-20 PA PA20028548601A patent/PA8548601A1/es unknown
- 2002-06-20 UY UY27344A patent/UY27344A1/es not_active Application Discontinuation
- 2002-06-20 AP APAP/P/2002/002559A patent/AP2002002559A0/en unknown
- 2002-06-20 SV SV2002001103A patent/SV2003001103A/es not_active Application Discontinuation
-
2003
- 2003-10-31 IS IS7014A patent/IS7014A/is unknown
- 2003-11-03 ZA ZA200308561A patent/ZA200308561B/xx unknown
- 2003-11-24 CR CR7163A patent/CR7163A/es not_active Application Discontinuation
- 2003-12-03 EC EC2003004875A patent/ECSP034875A/es unknown
- 2003-12-10 MA MA27430A patent/MA27034A1/fr unknown
- 2003-12-17 NO NO20035632A patent/NO20035632L/no not_active Application Discontinuation
- 2003-12-22 BG BG108486A patent/BG108486A/bg unknown
-
2005
- 2005-09-08 US US11/222,908 patent/US20060014788A1/en not_active Abandoned
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HN2002000153A (es) | Formulaciones autoemulsionantes de inhibidores de la proteina de transferencia de colesteril ester. | |
BR0307727A (pt) | Fomulação | |
DK1317177T3 (da) | Desinficerende formuleringer | |
BR0207961A (pt) | Combinação de análogos da epotilona e agentes quimioterápicos para o tratamento de doenças proliferativas | |
CY1112687T1 (el) | Μεθοδος για χρηση δικετοπιπεραζινων και συνθεσεις που περιλαμβανουν αυτες | |
ATE289640T1 (de) | Amidofunktionelle aminopolydiorganosiloxane | |
DK0698393T3 (da) | 3-/-menthoxypropan-1,2-diol som solubiliseringsmiddel og præparat til udvortes brug, der indeholder samme | |
ES2176700T3 (es) | Composiciones para la piel. | |
GT199800177A (es) | Combinacion eficaz para el tratamiento de la impotencia . | |
HN2000000166A (es) | Composicion de ovulos intravaginales de clindamicina | |
ECSP066481A (es) | Formulaciones que contienen cobre | |
DE60209020D1 (de) | Pestizide formulierungen | |
AR028031A1 (es) | Composicion biocida que comprende un gel aireado que contiene selice hidrofnbica | |
ATE263487T1 (de) | Flüssige formulierungen | |
DK1330258T3 (da) | Kahalalid F-formulering | |
DOP2001000219A (es) | Applicator | |
ES2120801T3 (es) | Composicion para la deformacion permanente de las fibras queratinicas, que contienen un antagonista de substancia p o un antagonista de cgrp. | |
DE60111207D1 (de) | Stabilisierte strahlungsquelle | |
FR2818814B1 (fr) | Source laser | |
NO20006447D0 (no) | Bölgeleder-laserkilde | |
ES2109632T3 (es) | Composicion de dentifrico anhidro. | |
BR0112600A (pt) | Compostos calcilìticos | |
NO20005548L (no) | Mykobakterieinhibitorer | |
DE50104331D1 (de) | Laserstrahlquelle | |
NO20032086D0 (no) | Adjuvant kombinasjonsformuleringer |